BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 34878918)

  • 1. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of latency-reversing agents on human macrophage physiology.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    Immun Inflamm Dis; 2023 Jan; 11(1):e590. PubMed ID: 36480653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S
    Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
    Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
    PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel
    Wong ME; Johnson CJ; Hearps AC; Jaworowski A
    J Virol; 2021 Sep; 95(19):e0022721. PubMed ID: 34287050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
    Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
    Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
    Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
    Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
    Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
    EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
    Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective BCL-X
    Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
    J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.
    Garcia-Vidal E; Badia R; Pujantell M; Castellví M; Felip E; Clotet B; Riveira-Muñoz E; Ballana E; Esté JA
    Antiviral Res; 2019 Aug; 168():18-27. PubMed ID: 31077767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
    Washizaki A; Murata M; Seki Y; Kikumori M; Tang Y; Tan W; Wardani NP; Irie K; Akari H
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracking HIV Rebound following Latency Reversal Using Barcoded HIV.
    Marsden MD; Zhang TH; Du Y; Dimapasoc M; Soliman MSA; Wu X; Kim JT; Shimizu A; Schrier A; Wender PA; Sun R; Zack JA
    Cell Rep Med; 2020 Dec; 1(9):100162. PubMed ID: 33377133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4
    Zerbato JM; Tachedjian G; Sluis-Cremer N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.